RT Journal Article
SR Electronic
T1 Dietary amino acids and risk of stroke subtypes: a prospective analysis of 356,000 participants in seven European countries
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.15.23294122
DO 10.1101/2023.08.15.23294122
A1 Tong, Tammy Y.N.
A1 Clarke, Robert
A1 Schmidt, Julie A.
A1 Huybrechts, Inge
A1 Noor, Urwah
A1 Forouhi, Nita G.
A1 Imamura, Fumiaki
A1 Travis, Ruth C.
A1 Weiderpass, Elisabete
A1 Aleksandrova, Krasimira
A1 Dahm, Christina C.
A1 van der Schouw, Yvonne T.
A1 Overvad, Kim
A1 Kyrø, Cecilie
A1 Tjønneland, Anne
A1 Kaaks, Rudolf
A1 Katzke, Verena
A1 Schiborn, Catarina
A1 Schulze, Matthias B.
A1 Mayen-Chacon, Ana-Lucia
A1 Masala, Giovanna
A1 Sieri, Sabina
A1 de Magistris, Maria Santucci
A1 Tumino, Rosario
A1 Sacerdote, Carlotta
A1 Boer, Jolanda M.A.
A1 Verschuren, W.M. Monique
A1 Brustad, Magritt
A1 Nøst, Therese Haugdahl
A1 Crous-Bou, Marta
A1 Petrova, Dafina
A1 Amiano, Pilar
A1 Huerta, José María
A1 Moreno-Iribas, Conchi
A1 Engström, Gunnar
A1 Melander, Olle
A1 Johansson, Kristina
A1 Lindvall, Kristina
A1 Aglago, Elom K.
A1 Heath, Alicia K.
A1 Butterworth, Adam S.
A1 Danesh, John
A1 Key, Timothy J.
YR 2023
UL http://medrxiv.org/content/early/2023/08/16/2023.08.15.23294122.abstract
AB Background Previously reported associations of protein-rich foods with stroke subtypes have prompted interest in assessment of individual amino acids. We examined the associations of dietary amino acids with risks of ischaemic and haemorrhagic stroke in the EPIC study.Methods We analysed data on 356,142 participants from seven European countries. Dietary intakes of 19 individual amino acids were assessed using validated country-specific dietary questionnaires, calibrated using additional 24-hour dietary recalls. Multivariable-adjusted Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of ischaemic and haemorrhagic stroke in relation to intake of each amino acid. The role of blood pressure as a potential mechanism was assessed in 267,642 (75%) participants.Results After a median follow-up of 12.9 years, 4,295 participants had an ischaemic stroke and 1,375 participants had a haemorrhagic stroke. After correction for multiple testing, higher intake of proline (as percent of total protein) was associated with 12% lower risk of ischaemic stroke (HR per 1 SD higher intake 0.88; 95% CI 0.82, 0.94). The association persisted after mutual adjustment for all other amino acids, systolic and diastolic blood pressure. The inverse associations of isoleucine, leucine, valine, phenylalanine, threonine, tryptophan, glutamic acid, serine and tyrosine with ischaemic stroke were each attenuated with adjustment for proline intake. For haemorrhagic stroke, no statistically significant associations were observed in the continuous analyses after correcting for multiple testing.Conclusion Higher proline intake was associated with a lower risk of ischaemic stroke, independent of other dietary amino acids and blood pressure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a Nuffield Department of Population Health Fellowship (TYNT), the UK Medical Research Council (MR/M012190/1), Cancer Research UK (C8221/A19170 and 570/A16491), and the Wellcome Trust (Our Planet Our Health, Livestock Environment and People 205212/Z/16/Z). EPIC-CVD has been supported by the European Union Framework 7 (HEALTH-F2-2012-279233), the European Research Council (268834), the UK Medical Research Council (G0800270 and MR/L003120/1), the British Heart Foundation (SP/09/002 and RG/08/014 and RG13/13/30194), and the UK National Institute of Health Research. The establishment of the study subcohort was supported by the EU Sixth Framework Programme (FP6) (grant LSHM_CT_2006_037197 to the InterAct project) and the Medical Research Council Epidemiology Unit (grants MC_UU_12015/1 and MC_UU_12015/5). The coordination of the European Prospective Investigation into Cancer and Nutrition (EPIC) is financially supported by International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF) (The Netherlands), and Statistics Netherlands is acknowledged for providing the causes of death; Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology - ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten and the funds supporting the Northern Sweden Diet Database (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford) (United Kingdom). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided written informed consent, and the study protocol was approved by the ethical review board of IARC and the institutions where the participants were recruitedI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesFor information on how to submit an application for gaining access to EPIC data and/or biospecimens, please follow the instructions at http://epic.iarc.fr/access/index.php